Cancer‐related inflammation: An emerging prognostic domain in metastatic castration‐resistant prostate carcinoma

E-ISSN： 1097-0142|120|21|3272-3274

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.21, 2014-11, pp. : 3272-3274

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio

CANCER, Vol. 120, Iss. 21, 2014-11 ,pp. : 3346-3352

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 833-839

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabazitaxel for the therapy of metastatic castration‐resistant prostate cancer in the aftermath of the CHAARTED trial

BJU INTERNATIONAL, Vol. 116, Iss. 6, 2015-12 ,pp. : 839-840

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is angiogenesis still an attractive target in metastatic castration‐resistant prostate cancer?

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 500-501

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite